Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,090 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale and Design of the CANONICAL Study　- Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus.
Kasama S, Masuyama T, Uemura S, Sato Y, Hiramitsu S, Masuda I, Yamamoto K, Komatsu S, Anzai T, Nishimura K, Ueda T, Kasahara M, Tanaka H, Susuta Y, Saito Y. Kasama S, et al. Among authors: komatsu s. Circ Rep. 2019 Aug 3;1(8):347-351. doi: 10.1253/circrep.CR-19-0049. Circ Rep. 2019. PMID: 33693161 Free PMC article.
Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes.
Ueda T, Kasama S, Yamamoto M, Nakano T, Ueshima K, Morikawa Y, Kawata H, Yoshihisa A, Nakayama M, Komatsu S, Soeda T, Watanabe M, Kawakami R, Okada Y, Tanaka H, Susuta Y, Kasahara M, Tsujita K, Takeishi Y, Saito Y; CANONICAL Study Group. Ueda T, et al. Among authors: komatsu s. Circ Rep. 2021 Jul 22;3(8):440-448. doi: 10.1253/circrep.CR-21-0030. eCollection 2021 Aug 10. Circ Rep. 2021. PMID: 34414333 Free PMC article.
CCL2/CCR2/Erk Signal Induced through Cancer Cell-Macrophage Interaction Contributes to Hepatocellular Carcinoma Progression.
Ishihara N, Koma YI, Omori M, Komatsu S, Torigoe R, Yokoo H, Nakanishi T, Yamanaka K, Azumi Y, Tsukamoto S, Kodama T, Nishio M, Shigeoka M, Yokozaki H, Fukumoto T. Ishihara N, et al. Among authors: komatsu s. Am J Pathol. 2025 Jan 3:S0002-9440(24)00480-2. doi: 10.1016/j.ajpath.2024.12.007. Online ahead of print. Am J Pathol. 2025. PMID: 39756577 Free article.
Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Ishihara N, Komatsu S, Yano Y, Fujishima Y, Ishida J, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Matsuura T, Tada T, Kodama Y, Fukumoto T. Ishihara N, et al. Among authors: komatsu s. Anticancer Res. 2025 Jan;45(1):251-260. doi: 10.21873/anticanres.17412. Anticancer Res. 2025. PMID: 39740814
2,090 results